AmerisourceBergen Settlement On Injectable Drug Repackaging Includes Forfeiture Of Exec Pay
Corporate integrity agreement attached to second DOJ settlement over repackaging of injectable cancer drugs would require recoupment of exec performance pay following misconduct.
You may also be interested in...
Fallout from Supreme Court's Escobar decision and Department of Justice memos could impact types of healthcare fraud complaints in which the government intervenes.
DOJ settlements totaling $269m resolve two False Claims Act cases; company enters corporate integrity agreement requiring independent review organization to assess claims.
$25m settlement resolves allegations covering 2006-2008 period; Abbott inked $1.5bn settlement with government six years ago involving Depakote promotion. This is DOJ's fourth pharma deal of the year.